Clinical Trial Detail

NCT ID NCT02887976
Title Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
Recruitment Completed
Gender male
Phase Phase III
Variant Requirements No
Sponsors GU Research Network, LLC
Indications

prostate cancer

Therapies

Abiraterone + Methylprednisolone

Age Groups: adult senior

No variant requirements are available.